Posted by Defense World Staff on Apr 9th, 2023
Allspring Global Investments Holdings LLC cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 55.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,859 shares of the company’s stock after selling 132,516 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.08% of Henry Schein worth $8,455,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the business. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Henry Schein by 2.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock valued at $459,000 after purchasing an additional 122 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its stake in shares of Henry Schein by 3.4% during the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company’s stock worth $321,000 after acquiring an additional 161 shares in the last quarter. Wetherby Asset Management Inc. increased its stake in shares of Henry Schein by 1.6% during the 1st quarter. Wetherby Asset Management Inc. now owns 10,860 shares of the company’s stock worth $947,000 after purchasing an additional 171 shares in the last quarter. Sepio Capital LP increased its position in Henry Schein by 2.8% during the 3rd quarter. Sepio Capital LP now owns 6,442 shares of the company’s stock worth $424,000 after purchasing an additional 175 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in Henry Schein by 2.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 9,052 shares of the company’s stock valued at $595,000 after acquiring an additional 180 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.
Insider Activity at Henry Schein
In related news, Director Philip A. Laskawy sold 6,405 shares of the stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $78.74, for a total value of $504,329.70. Following the sale, the director now directly owns 26,239 shares in the company, valued at approximately $2,066,058.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Kurt P. Kuehn sold 1,909 shares of the company’s stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the transaction, the director now directly owns 15,675 shares of the company’s stock, valued at approximately $1,214,185.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Philip A. Laskawy sold 6,405 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $78.74, for a total value of $504,329.70. Following the completion of the transaction, the director now owns 26,239 shares of the company’s stock, valued at approximately $2,066,058.86. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
HSIC has been the subject of a number of research reports. Credit Suisse Group decreased their target price on Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a report on Tuesday, February 28th. Morgan Stanley reduced their price objective on Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research report on Tuesday, February 21st. UBS Group raised their target price on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. StockNews.com upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Barrington Research decreased their price objective on shares of Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a report on Friday, February 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $85.89.
Henry Schein Stock Performance
NASDAQ:HSIC opened at $84.73 on Friday. The firm has a 50 day moving average of $81.78 and a 200-day moving average of $78.19. Henry Schein, Inc. has a 1 year low of $64.75 and a 1 year high of $92.68. The stock has a market capitalization of $11.12 billion, a P/E ratio of 21.78, a price-to-earnings-growth ratio of 1.94 and a beta of 0.81. The company has a current ratio of 1.79, a quick ratio of 0.91 and a debt-to-equity ratio of 0.25.
Henry Schein (NASDAQ:HSIC – Get Rating) last announced its earnings results on Thursday, February 16th. The company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.21 by $0.14. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. The company had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same quarter in the prior year, the business earned $1.07 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Intuitive Surgical Price Target Increased to $315.00 by Analysts at Bank of America
Intuitive Surgical Price Target Raised to $325.00 at Truist Financial
Atlassian Co. Shares Sold by Great Valley Advisor Group Inc.
Kestra Private Wealth Services LLC Purchases New Holdings in Teradyne, Inc.
Great Valley Advisor Group Inc. Decreases Stake in Boston Properties, Inc.